SANO GENETICS

Company Overview

Sano Genetics connects people with research in personalized medicine by offering free genome sequencing and analysis for research participants. The company charges researchers for tools to analyze anonymous and aggregated data provided by these individual users. Sano employs NGS platforms to perform WES and WGS.

Sano has developed a data-sharing platform that allows people to submit their medical and genetic data in order to be matched with research studies that could benefit from the information. In exchange, the individual gets a personalized health report.

In September 2019, Sano Genetics partnered with GenePlaza to help individuals who have used DTC genetic tests to tie into clinical trials and other research programs. GenePlaza markets a suite of web-based applications that customers can use to interpret data from DTC genetic tests. As part of this partnership, GenePlaza began offering an app through which its customers can review and opt into research projects through Sano’s platform.

In July 2020, Sano formed an alliance with Genomics England and Zetta Genomics to develop a new software tool that will enable genomics research project participants with rare diseases to better self-report information and receive updates. This tool, to be introduced in 2021, could also have other applications in other indications, for example, cancer.

In October 2020, Sano Genetics and the University of Manchester (U.K.) agreed to collaborate on a new project to translate genetic eye disease research into clinical applications. The partners agreed to work together to create a database of genomic- and patient-reported data to identify how genetic can impact disease outcome.

Company's Business Segments

• Product : Precision Medicine Research Platform, Digital Trial Management Tools, Others
• Service : Recruitment Support, Prescreening and Digital Consent, Electronic Medical Record Retrieval, DNA Testing, Patient Engagement